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Abstract
Progress in understanding the molecular basis of melanoma has made possible the identification of molecular
targets with important implications in clinical practice. In fact, new therapeutic approaches are emerging from
basic science and it will be important to implement their rapid translation into clinical practice by active clinical
investigation.
The first meeting of Melanoma Research: a bridge Naples-USA, organized by Paolo A. Ascierto (INT, Naples, Italy)
and Francesco Marincola (NIH, Bethesda, USA) took place in Naples, on 6-7 December 2010.
This international congress gathered more than 30 international and Italian faculty members and was focused on
recent advances in melanoma molecular biology, immunology and therapy, and created an interactive discussion
across Institutions belonging to Government, Academy and Pharmaceutical Industry, in order to stimulate new
approaches in basic, translational and clinical research. Four topics of discussion were identified: New pathways in
Melanoma, Biomarkers, Clinical Trials and New Molecules and Strategies.
Introduction
Before reporting the interesting data that emerged from
the debate [1,2] there is merit in mentioning discussions
about the impact of biomedical research on health and
wealth. In fact, the first topic addressed was the impact
of biomedical research on health and wealth in USA.
Over the past 30 years, total national spending on
health care has more than doubled as a share of Gross
Domestic Product (GDP). Health Care Expenditure Pro-
jections suggest that health care costs will continue to
account for a steadily growing share of GDP, reaching
41 percent by 2060 and 49 percent by 2082. Biomedical
research is, indirectly, one of the major drivers of health
care costs and at least 50% of this increased cost is attri-
butable to it. Broadly, Federal funds for Research and
Development compete with other priorities in the Fed-
eral budget and their investment is sometimes criticized
for lack of results or use in non-essential projects.
Therefore it was necessary to develop a strategy to
document the outcomes of science investments to the
public and to ensure that resources are allocated wisely.
The STAR METRICS (Science and Technology for
America’s Reinvestment: Measuring the Effect of
Research on Innovation, Competitiveness and Science)
project is a partnership between science agencies and
research institutions and promises to document with
solid evidence the returns that the USA is obtaining
from its investment in research and development. The
program is structured in two phases. The first phase will
develop uniform, auditable and standardized measures
of the impact of science spending on job creation, using
data from research institutions’ existing database
records. The second phase will measure the impact of
Federal science investment on four key areas: scientific
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knowledge (using metrics such as publications and cita-
tions), social outcomes (e.g. health outcomes measures
and environmental impact factors), workforce outcomes
(e.g. student mobility and employment), and economic
growth (e.g. tracing patents, new company start-ups and
other measures). Data for the program will come from
research institutions that volunteer to participate and
the federal agencies that fund them. Information will be
gathered from the universities in a highly automated
way, with minimal or no burden for the scientists and
the university administration. This initiative provides a
new way to measure the impact of federally funded
research, so that the public will have an informed pic-
ture of the benefits obtained from the money spent [3].
New Pathways In Melanoma
Genetic alterations, somatic or inherited, play a role in
the pathogenesis of melanoma. The relevance of identi-
fying genetic variants, their roles in critical pathways
and in development of aggressive phenotypes in order
to find new targets for melanoma therapy have been
discussed.
Genetic variants in melanoma susceptibility and
pathogenesis lead to different molecular subsets of mela-
nomas. Immunohistochemical and mutational analysis
showed that inactivation and impairments of the
p16CDKN2A gene are present at steadily increasing
rates as lesions move from primary melanoma to mela-
noma metastases, correlating with progression of disease
and cell proliferation. Relative risk of carrying a
CDKN2A mutation for melanoma patients was demon-
strated to significantly increase with the presence of
familial occurrence of melanoma (likelihood of
CDKN2A germline mutations increases according to
number of affected members in the family), multiple pri-
mary melanomas, and early age of onset. Based on such
clinical predictors for germline mutations, standardized
criteria have been elaborated to select putative carriers
of mutations, who are at risk of developing not only
melanoma but also pancreatic carcinoma. In Italy, the
prevalence of CDKN2A mutations may vary widely
among patients with different geographical origins. In
particular, a higher frequency of CDKN2A germline
mutations has been observed in patients from Northern
Italy in comparison to those from Southern Italy. Muta-
tions in CDKN2A, CDKN2B, and CDK4 genes are
reported to be absent in Sardinian patients; in such a
population, germline mutations in BRCA2 gene and
multiple MC1R variants contribute to melanoma sus-
ceptibility. More generally, MC1R variants seem to
increase melanoma risk in families with CDKN2A muta-
tions and CDKN2A mutation carriers with MC1R var-
iants have a statistically significant lower median age at
diagnosis. Recently, a synergistic relationship between
germline MC1R variants and somatic BRAF mutations
has been suggested, whereby MC1R variant genotypes
seem to confer a significantly increased risk of develop-
ing BRAF-mutant melanoma in skin not damaged by
sunlight. It has been hypothesized that intermittent sun
exposure may indirectly induce BRAF mutations
through the impairment of MC1R and an increased pro-
duction of free radicals. Since this correlation has not
been confirmed in Australia, one could again speculate
that differences in patients’ geographical origins and/or
the genetic backgrounds of patient populations may play
an important role in determining such geographical
discrepancies.
Additional information about melanoma susceptibility
could be obtained from genome-wide association studies
(GWAS) which aim to identify common genetic variants
contributing to melanoma risk. Worth mentioning is the
recently-described association between the CDKN2A
locus and nevus formation as well as susceptibility to
melanoma alone or melanoma and basal cell carcinoma.
Although several other genes have been associated with
the melanoma risk only (MC1R) or with susceptibility to
melanoma and basal cell carcinoma (TYR, ASIP, and
TYRP1 - which represent the major determinants of
hair and skin pigmentation), their role in melanoma
development remains unclear. On the basis of this evi-
dence, a complex connection of molecular mechanisms
has been implicated in melanomagenesis, raising the
need to address alternative genetic progression models
rather than the multi-step linear models used so far. In
fact, the different molecular mechanisms may have sepa-
rate roles or cooperate during all evolutionary phases of
melanocytic tumorigenesis: not one but several roads
lead to melanoma. Focusing mainly on BRAF, evidence
has been provided suggesting the lack of close correla-
tion in pathogenetic mutations between primary tumor
and metastasis from the same patients. This could be
explained by the presence of polyclonality in the pri-
mary tumor, similar to the recent finding for melanocy-
tic nevi and in line with the recent stem cells
progression model. Therefore, different molecular
mechanisms generate different subsets of melanoma
patients with distinct aggressiveness, clinical behavior,
and response to therapy. In this sense, characterization
of molecular mechanisms could contribute to better
classification of the different subsets of melanoma
patients and might be useful to optimally managing mel-
anoma patients with differencing prognosis as well as to
better address the most effective therapy for different
melanoma subsets.
Along this line, results from sequencing the melanoma
transcriptome and exome have generated new insights
into melanoma biology. High-throughput sequencing by
Illumina GA of tumor cDNA and exons of about 16,000
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genes captured by NimbleGen arrays from tumor DNA
and matching germline DNA isolated from circulating
lymphocytes or skin cells, provide an unprecedented
overview of novel somatic and inherited mutations in
melanoma. The current experience indicates that the
number of somatic variants is highly variable depending
on the type of melanoma. The highest number of
somatic variants was observed in a desmoplastic mela-
noma excised from the forehead. High prevalence of UV
signature C > T mutations was observed in melanomas
from sun-exposed lesions. In the absence of frequent
novel recurrent mutations in specific genes such as in
BRAF and NRAS, the bioinformatic analysis revealed
mutations in novel genes belonging to signaling path-
ways involved in cell cycle control, proliferation, cell-cell
interaction, cell-stroma interaction, adhesion, movement
and spreading, or genes that can promote drug resis-
tances. The focus is currently on identifying mutations
in functional groups involved in activities characteristic
of the malignant phenotype with a priority on kinases or
other enzymes with potential to be therapeutic targets.
Exposure to an embryonic stem cell (hESC) microen-
vironment reprograms the metastatic phenotype of
aggressive melanoma cells resulting in the re-expression
of melanocyte-specific markers and a reduction in inva-
sive potential. Regulation of the re-emergence of Nodal
signaling in tumor cells is one of the possible molecular
mechanisms underlying reversion of the metastatic phe-
notype. To better characterize the role of Nodal, the
expression of key components of the Nodal signaling
pathway was examined in human normal, neoplastic
and hESC types. Given the significant observation that
like hESCs, cancer cells express Nodal, although unlike
hESCs, they do not express Lefty (Nodal’s inhibitor),
it was hypothesized that hESC-derived Lefty and possi-
bly other tumor-suppressive factors found in hESC-
conditioned matrices (CMTX), reprogram metastatic
melanoma cells by inhibiting Nodal signaling. Further
analysis showed that exposure to hESC CMTX down-
regulates Nodal expression in metastatic melanoma cells
and that this effect is reversible over time. Moreover,
knock down of Lefty in hESC CMTX results in the up-
regulation of Nodal. It has also been shown that another
protein is involved in Nodal expression regulation.
Indeed, the Nodal gene has a node specific enhancer
(NDE) that is active in aggressive melanoma cells in a
Notch-dependent manner. In particular, Notch4 is spe-
cifically required for expression of Nodal in aggressive
cells and plays a vital role both in the balance of cell
growth and in the regulation of the aggressive pheno-
type. Inhibition of Notch4 signaling blocks vasculogenic
mimicry and anchorage independent growth. These data
regarding Nodal signaling and its regulation offer a
potential molecular target for melanoma therapy. In
future Nodal may be regarded as a prognostic factor
since Nodal expression is associated with vertical growth
in dysplastic nevi; melanoma in situ showed lower levels
of Nodal than deep melanoma and metastatic melano-
mas. In patients with a previous history of melanoma
there was a positive correlation between high Nodal
expressing nevi and melanoma Breslow depth.
Finally, it will be important to identify biomarkers that
in the future may become a target for molecular therapy
of melanoma. One possible approach is cDNA microar-
ray analysis, which has enabled the identification of
putative melanoma biomarkers by virtue of their differ-
ential expression in distinct phases of melanoma pro-
gression [4]. Application of cDNA microarray analysis
has, for example, led to the development of multi-
marker diagnostic [5] and prognostic [6,7] assays that
are nearing clinical application. More recently, this
approach has led to the discovery that PHIP, involved in
the IGF pathway, represents a positive prognostic factor
for melanomas that overexpress it. Overall, new results
are emerging about the identification of progression bio-
markers that can predict the ability of melanoma to
metastasize to lymph nodes or to distant sites. These
biomarkers can be used to identify patients at higher
risk of relapse or death who may be candidates for sen-
tinel lymph node biopsy or adjuvant therapy and may
also represent possible novel targets for the molecular
therapy of melanoma.
Biomarkers In Melanoma
The hypothesis that cancer is driven by tumor-initiating
cells (known as cancer stem cells) has recently attracted
attention, owing to the promise of a novel cellular target
for the treatment of solid malignancies. Furthermore, it
seems that tumor-initiating cells might be resistant to
many conventional cancer therapies, which might explain
the limitations of these agents in curing human malig-
nancies. For this reason, there is a need to find markers
that serve to identify tumor-initiating cells and thus facil-
itate development of therapeutic strategies to target these
cells. ABCB5, an ATP-binding cassette (ABC) family
member, in combination with aldehyde dehydrogena-
se1A1 identifies melanoma initiating cells, since these
cells in low numbers can induce tumors in immunodefi-
cient mice. These cells are sensitive to cyclopamine, an
inhibitor of the hedgehog signaling pathway, but are
resistant to paclitaxel. Melanoma initiating cells are sen-
sitive to BRAF inhibitors. Their antiproliferative activity
can be enhanced by monoclonal antibodies specific for
the membrane bound chondroitin sulphate protidoglycan
4 (CSPG4), a tumor antigen which plays an important
role in the biology of malignant cells.
The efforts in biomarker identification relevant to
immune mediated tumor rejection, mechanisms of
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therapeutic intervention and prediction of clinical out-
come have been advanced by application of high
throughput molecular technologies. Using minimally
invasive needle biopsies, the same lesion can be moni-
tored at the whole transcriptome level at different stages
along the natural history of melanoma or during thera-
peutic intervention. Studies based on gene expression
profiling in identical lesions before and after different
types of immune therapy demonstrated a unique mole-
cular signature in the tumor microenvironment when
rejection occurs. Among these signature genes, IRF1
(IFN regulatory factor 1) up regulation has been the key
immune modulator associated with responsiveness not
only in melanoma but also in the response of genital
warts to imiquimod, carcinoid tumors to IFN-a and
CML to IFN-a. High dose IL-2 induced melanoma
regression is associated with up regulation of NKGC5, T
cell receptor alpha chain and HLA II related transcripts.
Those genes have also been reported in association with
acute rejection of renal allografts. The best self con-
trolled melanoma study is the analysis of patients with
mixed treatment responses. With identical genetic make
up and immune pressure, the differences between the
phenotypes of separate and distinct lesions emphasize
the importance of tumor microenvironment. This study
revealed that antigen presentation machinery in respon-
sive metastases was significantly enhanced compare with
progressive lesions. In the mechanism of rejection study,
local applications of the TLR-7 agonist imiquimod for
the treatment of basal cell cancer revealed earliest upre-
gulated cytokine receptor CXCR3, a ligand for IP-10
and monokine induced by IFN (MIG/CXCL9), suggest-
ing its early involvement in the crosstalk leading to
migration and activation of monocytes and lymphocytes.
With regard to prediction of immune responsiveness
and survival, Wang identified 100 genes with significant
differential expression by TILs from 13 complete
responders and 40 non-responders. However, when the
tumors that were the source of the TILs were studied,
no clear predictors of their phenotype could be identi-
fied, suggesting that response or progression could
result from intrinsic genetics of the patient rather than
the specific genetics of the tumor. In conclusion, clinical
outcomes of patients treated by immune therapy are
determined by multiple factors that may be redundant,
synergistic or contrasting. To fully understand each
component’s contribution to the outcome, a system
biology approach should be applied.
Emerging molecular genetic techniques will increas-
ingly be used to supplement skilled morphological tissue
assessment, to optimize management of melanoma
patients by increasing accuracy of diagnosis, permitting
individualized prognostication and guiding optimal ther-
apy. Fluorescence in Situ Hybridization (FISH),
Comparative Genomic Hybridization (CGH), Gene
microarrays (gene signatures) and Gene sequencing are
techniques that can supplement the histological diagno-
sis of non classical melanocytic lesions such as border-
line lesions, atypical spitzoid lesions, atypical cellular
blue nevi, deep penetrating nevi, pigmented epithelioid
melanocytomas etc. In fact, gene expression microarray
hierarchical clustering maps will likely have the capacity
to separate melanomas from nevi, identify different (his-
tologically challenging) patterns of primary melanomas
and clearly distinguish primary melanomas from sentinel
node metastases. In preliminary studies the majority of
differentially expressed genes (genes with the greatest
fold-change between primaries and metastases) were
genes that were decreased in metastases (S100A8,
TACSTD2, SERPINB5, CLCA2, MMP1). Some genes
were increased (MAGE family, PRKCB). Relatively
increased keratinocyte-related genes in primary melano-
mas likely represent contamination of the tumor tissues
by structures such as sweat ducts and glands. Informa-
tion gained from studies of this type may provide under-
standing of the molecular events that underpin
lymphatic invasion. In turn this will lead to recognition
of the biomarkers that identify primary tumors with the
potential for lymphatic extension.
Patients with melanoma have a predominant and early
involvement of immunological dysfunctions affecting
myeloid cells. Particularly, CD14+HLA-DRneg/low repre-
senting bona fide myeloid derived suppressor cells
(MDSC) in this tumor histology [8], accumulate in per-
ipheral blood of melanoma patients since the very
beginning of the disease (stage IIB and C) and can be
detected as infiltrating components of primary lesions,
suggesting a potential involvement of these cells in mel-
anoma progression. CD14+HLA-DRneg/low sponta-
neously release a large array of immunosuppressive and
pro-tumorigenic cytokines and chemokines, and inhibit
proliferation and function of activated T cells mostly
through TGFb secretion. Since patients with lower fre-
quency of CD14+HLA-DRneg/low and lower TGFb serum
levels mount better immune responses to anti-tumor
vaccine [8], CD14+HLA-DRneg/low down-modulation
could be an opportunity to enhance immunotherapy. In
this view studies are undergoing to identify potential
pharmacological tools interfering with MDSC differen-
tiation and function both in vitro and in vivo, in mela-
noma patients.
Cancer alters immune function via multiple mechan-
isms. To gain insights into the molecular mechanisms of
immune dysfunction in cancer, gene expression profiles
of peripheral blood lymphocytes (PBLs) from 12 patients
with melanoma was compared to PBLs from 12 age-
matched healthy controls. Of 25 significantly altered
genes in T cells and B cells from melanoma patients,
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20 were interferon (IFN)-stimulated genes (ISG). The
functional response of lymphocytes to IFN stimulation
was assessed by measurement of STAT1 phosphoryla-
tion (pSTAT1), an essential event in signal transduction
by IFNs. The median percentage of phosphorylated
STAT1-positive lymphocytes induced by IFN-stimula-
tion was significantly reduced in patients with mela-
noma compared to healthy controls. In a subsequent
study, it was shown that ISG expression is also reduced
in PBLs from breast cancer patients. IFN-a-induced
pSTAT1 is reduced in T cells, B cells and NK cells from
breast cancer, melanoma and gastrointestinal cancer
patients, while IFN-g-induced pSTAT1 is reduced in B
cells from all three cancer patient groups. Age is asso-
ciated with decreased STAT1 responsiveness to IFN-a
in melanoma.
These defects in IFN signaling are not influenced by
chemotherapy, and the impairment in IFN signaling can
be partially overcome by prolonged, high dose IFN-a.
Moving beyond IFN signaling, three other JAK/STAT
signaling pathways are downregulated and one pathway
is upregulated in PBLs from melanoma patients. Thus,
there appears to be global alterations in immune signal-
ing networks necessitating use of Bayesian Network ana-
lysis to understand immune signaling networks in
melanoma. Clinical application of these data led to the
analysis of IFN signaling in lymphocytes from melanoma
patients (stages IIIB or IIIC) pre- and post-HDI, and
correlation with clinical response and outcome. Mela-
noma patients who had a clinical response to HDI ther-
apy over the 4-week induction phase of neo-adjuvant
therapy had a significant increase in the fold induction
of pSTAT1 in peripheral blood T cells during IFN-
stimulation from day 0 to day 29 and this correlated
with good clinical outcome. Increase in pSTAT1 may be
used to guide selection of patients for continued HDI
therapy. The sample size of this study was too small
(16 patients) to be conclusive, but these results indicate
the need for a larger confirmatory study [[9,10], and
Simons DL, Lee G, Kirkwood JM, and Lee PP. Interferon
Signaling Patterns in Peripheral Blood Lymphocytes
may Predict Clinical Response and Outcome after
High-Dose Interferon Therapy in Melanoma Patients.
Submitted.].
Some strategies augment vaccine efficacy, demonstrat-
ing that successful immunotherapy of melanoma will
require interventions that reduce the number or func-
tion of Treg cells. Studies in mice suggest that vaccina-
tion of reconstituted lymphopenic hosts could elicit
superior anti tumor immunity relative to normal hosts,
highlighting the potential clinical benefit of performing
tumor vaccination during immune reconstitution. How-
ever lymphopenic mice reconstituted with spleen cells
from tumor-bearing mice (TBM) failed to generate
tumor-specific T cells with therapeutic efficacy. Clinical
trials in reconstituted lymphopenic patient showed that
immediately following vaccination the absolute number
of dividing Treg cells in peripheral blood is increased
and the majority of Treg come from the reinfusion pro-
duct. Therefore it was considered of interest to ex vivo
deplete CD25+Treg from TBM spleen cells prior to
reconstitution and vaccination: this strategy fully
restored the generation of therapeutic effector T cells,
even in animals with established tumor burden. Given
these results a translational clinical trial in patients with
metastatic melanoma has been initiated to exploit lym-
phopenia to augment the adoptive immunotherapy of
melanoma patients. Preliminary studies of Helios protein
expression in patients adoptively transferred with CD25-
depleted PBMC and vaccinated following non myeloa-
blative chemotherapy suggests that the majority of early
recovering Treg are not thymus-derived. This suggests a
critical role for the tumor milieu in promoting the
recovery of Tregs. How can we interfere with the capa-
city of the tumor/tumor-bearing environment to gener-
ate tumor-induced Treg and promote the development
of natural Treg? There are various options currently in
study such as TGFb blockade and anti-OX40 that can
prevent generation of tumor-induced Treg in preclinical
models. Another option is partial CD4 depletion that
reduces Treg number and recovers tumor-specific and
therapeutic T cell function in preclinical models.
A number of these strategies are in clinical trials and
combination studies that include vaccines are considered
promising.
Clinical Trials
Melanoma therapy has been difficult over the past
30 years, with many negative trials and the absence of
any predictive markers for the few existing therapeutic
agents. Adjuvant therapy of melanoma is the setting
that may lend itself to the improvement of treatment
given the series of studies of the ECOG and US Inter-
group known as E1684, E1690, E1694, and the meta-
analysis of all trials of IFN-a, which have confirmed a
durable and significant impact of this therapy upon
relapse-free and overall survival. Two approaches have
been adopted to improve the relative magnitude and
risk-benefit ratio for IFN-a: refine risk assessment,
focusing treatment upon patients with greatest risk of
relapse; and to refine therapeutic target, focusing treat-
ment upon patients with greatest chance to benefit. For
example, patients with high risk resected melanoma
were studied to evaluate whether a high baseline or
increasing serum S100B is an independent prognostic
marker of risk for mortality. The studies [11] recently
published concerning S100B have demonstrated that
this marker allows us to refine the risk profile of
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melanoma and suggest that future studies of other risk
biomarkers may add to our prognostic assessment of
patients for adjuvant therapy. On the other hand, the
appearance of autoantibodies or clinical manifestations
of autoimmunity during treatment with interferon alfa-
2b has been shown to be associated with statistically
significant improvements in relapse-free survival and
overall survival benefit of IFN therapy in patients with
resected melanoma. Furthermore, baseline cytokine
levels predict 5-year relapse-free survival with high-dose
IFN-a. In conclusion profiling of sera from patients
treated with HD-IFN identifies potential predictors of
adjuvant therapeutic benefit. An unresolved question in
adjuvant therapy with IFN-a is what the optimal dura-
tion of treatment may be. The results of the study
E1697, which was designed to assess whether one
month of IV high-dose ‘induction’ therapy is sufficient
to improve relapse free and overall survival of inter-
mediate and high-risk stage IIA and IIIA melanoma has
been closed for futility in 2010. This demonstrates that
one month of high-dose IFN is not sufficient for adju-
vant therapy of high-risk patients, and argues that a year
of therapy remains the standard of treatment. Multiple
vaccine approaches, including the GSK DERMA phase
III trial, are studied and are currently under study in
adjuvant setting, but none has yet shown beneficial
results. Novel melanoma vaccine strategies are being
developed employing new CD8 killer T cell and CD4
helper T cell epitopes and utilizing polarized dendritic
cells, (alphaDC1) loaded with melanoma peptides. How-
ever, the next chapter in melanoma therapy is likely to
be comprised of the current active immunotherapy
agents like IL-2 and IFN-a-2 with new immunotherapies
such as the checkpoint inhibitors such as anti-CTLA4-
blocking antibodies, and anti-PD1. After positive results
in advanced disease, the adjuvant role of ipilimumab has
been tested in two studies: EORTC18071 (in which it is
compared to placebo) and ECOG E1609 in which it is
compared to High-dose IFN. Ipilimumab is also being
evaluated in a trial of neoadjuvant treatment that is
nearing completion at the University of Pittsburgh.
A better understanding of the biology of melanoma is
leading to the development of personalized treatment
based on genetic alterations, molecular markers, risk
classifiers and pharmacogenomics. Key studies with
BRAF inhibitors are currently ongoing and more are
starting. Despite profound responses, patients with
BRAF mutant tumors eventually develop resistance and
disease progression. Mechanisms of resistance are being
identified, and studies are designed with different strate-
gies to overcome this resistance. For example, new evi-
dence suggests that both the MAPK and PI3K/AKT
pathways can override BRAF inhibition and a combina-
tion blockade of both pathways after BRAF inhibitor
failure will be tested in a randomized phase II of com-
bined MEK inhibitor AZD6244 and AKT inhibitor
MK2206 versus MEK inhibitor alone in patients with
BRAF V600E mutant advanced unresectable melanoma
who previously failed a selective BRAF inhibitor. cKIT is
a target mainly in mucosal, acral and solar melanomas
that can be targeted with inhibitors such as nilotinib
and dasatinib. These are currently being studied in the
phase III TEAM trial (nilotinib against dacarbazine in
the treatment of metastatic and/or inoperable melanoma
harboring a c-Kit mutation) and the phase II E2607 trial
(dasatinib in patients with unresectable locally advanced
or stage IV mucosal, acral and solar melanomas). The
growing interest in the targeting of embryonic develop-
mental pathways has led to the identification of Notch
as a possible therapeutic target in melanoma. New
molecules such as inhibitors of g-secretase (GSI), a
molecule involved in the activation of Notch signaling
are currently in clinical development. RO4929097 is a
GSI being studied in melanoma in a pilot biomarker-
driven neoadjuvant study in resectable stage IIIB, IIIC,
or IV, in a phase II trial as single agent in advanced
unresectable or metastatic disease or in combination
with chemotherapy (phase Ib/II trial of RO GSI in com-
bination with cisplatin, vinblastine, and temozolomide in
patients with metastatic melanoma). For immunother-
apy, several studies are currently ongoing in advanced
melanoma to refine the application of ipilimumab
(dacarbazine and ipilimumab versus dacarbazine with
placebo, bevacizumab plus ipilimumab, ipilimumab in
patients with spontaneous preexisting immune response
to NY-ESO-1, and study of BMS-908662, a Raf inhibitor,
in combination with ipilimumab in subjects with
advanced melanoma). Additional studies are starting to
define the role of new molecules and novel combination
treatments (dose-escalation study of combination BMS-
936558, anti-PD1, and ipilimumab, biotherapy with afli-
bercept, VEGF-trap, and high dose IL-2 versus high
dose IL-2 alone, anti-PD1 in combination with multiple
class I peptide vaccines, or IL-12-based multipeptide
vaccination with T-reg depletion).
Active immunotherapy approach have been developed
this last decade, among which the clinical development
of ASCI (Antigen-Specific Cancer Immunotherapeutic).
This approach is aimed at educating the immune system
to eradicate cancer cells by targeting specific antigens
present on the tumors cells. MAGE-A3 antigen, one of
these specific tumor antigens, is expressed by up to 76%
of metastatic melanomas [12]. In a Phase I dose escala-
tion study, patients with metastatic MAGE-A3 positive
melanoma were immunized with recombinant MAGE-
A3 protein associated with the immunostimulant AS02B
to evaluate the safety profile and the clinical response
following immunization. All dosage levels were well
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tolerated and no dose-toxicity relationship was observed.
The clinical activity was mainly observed in early meta-
static disease and no differences in immunogenicity
were reported between different doses of protein tested
(30, 100, 300 mg) [13]. Then a Phase II study was
designed in patients with MAGE-A3 + cutaneous mela-
noma to evaluate MAGE-A3 recombinant protein com-
bined with different immunostimulants (AS) AS15 or
AS02B (NCT00086866). Results demonstrated that both
MAGE-A3 ASCI formulations were well tolerated, rec-
MAGE-A3 + AS15 seemed to be more active than rec-
MAGE-A3 + AS02B and showed long-lasting clinical
responses. The patients receiving recMAGE-A3 + AS15
also developed a more frequent and robust immune
response. The main outcome of this study was the selec-
tion of the AS15 as adjuvant system for further develop-
ment (Table 1) [14,15]. These results represent a second
positive signal of clinical activity for the MAGE-A3
ASCI. Clinical activity was also reported in a separate
double-blind, placebo-controlled Phase II study of
patients with NSCLC (NCT00290355) (Table 2) [16].
Both Phase II trials in NSCLC and melanoma patients
led to phase III trials initiation in melanoma (DERMA
trial, resected MAGE-A3 + pIIIB/pIIIC melanoma ran-
domized to recMAGE-A3 + AS15 or placebo -
NCT00796445) and NSCLC (MAGRIT trial, resected
MAGE-A3+ NSCLC pIB/II/IIIA randomized to rec-
MAGE-A3 + AS15 or placebo with or without prior
chemotherapy - NCT00480025) to show the efficacy of
the MAGE-A3 ASCI. Moreover, gene profiling of mela-
noma tumors taken prior to MAGE-A3 ASCI immuni-
zation has led to the identification of a gene signature
(GS) that may predict the clinical outcomes of MAGE-
A3 ASCI treatment. Most of the genes identified in the
GS were immune-related suggesting that the presence of
a specific tumor-environment prior to MAGE-A3 ASCI
treatment influences its efficacy. The predictive value of
the melanoma signature was also tested in NSCLC and
showed that patients with the GS are more likely, but
not certain, to benefit from MAGE-A3 ASCI immuniza-
tion (Table 3) [17]. The GS is currently under
validation.
The importance of immunostimulatory antibodies in
melanoma treatment was demonstrated in clinical trials
of anti-CTLA-4. Two anti-CTLA-4 antibodies, ipilimu-
mab and tremelimumab, are in clinical development,
both of which block a key co-inhibitory signal mediated
by the CTLA-4 receptor that regulates T-cell activation.
A randomized phase III trial of ipilimumab 3 mg/kg
every 21 days × 4 doses, compared to the gp-100 pep-
tide vaccine or the combination of the two in previously
treated metastatic melanoma patients, showed a signifi-
cant improvement in overall survival for both ipilimu-
mab arms over peptide vaccine alone. The results of the
trial will likely result in regulatory approval of ipilimu-
mab as a single agent. The most common adverse
events were immune-related and included rash, diarrhea,
endocrinopathies and hepatitis. Adverse events were
almost always reversible and manageable with immuno-
suppressive medications. Development of immune
related adverse events was associated but not necessary
for response in some trials. Promising data are emerging
from trials of anti-CTLA-4 in combination with other
immunomodulatory agents, for example, in a phase 1/2
of IL-2 + ipilimumab and a phase II of tremelimumab +
high-dose Interferon-a. Because of results from the
anti-CTLA-4 trials, there is growing interest in develop-
ing other antibodies targeting T-cell co-stimulatory and
co-inhibitory molecules. One of these, B7-H1, a recently
described member of the B7 family of costimulatory
molecules, is thought to be involved in the negative reg-
ulation of cellular and humoral immune responses
through the PD-1 receptor on activated T and B cells.
Expression of B7-H1 on mouse P815 tumor blocks the
potent anti-tumor effects generated by tumor expression
of the strong co-stimulatory signal B7.1. In the first sin-
gle-dose phase I clinical trial of PD-1 blockade with the
mAb MDX-1106, patients with advanced treatment
Table 1 Results from Phase II study in cutaneous metastatic melanoma [14,15]
Phase II Melanoma (NCT 00086866) recMAGE-A3 + AS02B recMAGE-A3 + AS15
Primary endpoint Clinical objective responses -
1 PR (5-months)
5 SD (> 16 weeks)
3 CR (11, 32+, 23+ months)
1 PR (7-months)
5 SD (> 16 weeks)
Secondary endpoints Safety Well tolerated Well tolerated
Overall survival 19.9 month
(95% CI: 15.4°; 25.6)
31.1 months
(95% CI: 20.0°; NR)
Cellular immune response Induced in 21% of patients Induced in 76% of patients
CR: Complete Response.
PR: Partial Response.
SD: Stable Disease.
CI: Confidence Interval.
NR: Not Reached.
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refractory solid tumors were treated in dose-escalating
six-patient cohorts at 0.3, 1, 3, or 10 mg/kg, followed by
a 15-patient expansion cohort at 10 mg/kg. Anti-PD-1
was well tolerated with only one serious adverse event,
inflammatory colitis, and produced one partial response
and one mixed response among 10 metastatic melanoma
patients. A second phase I trial evaluated the safety and
antitumor activity of MDX-1106 administered every two
weeks at doses of 1, 3, or 10 mg/kg. An MTD was not
reached, and subsequently up to a total of 16 patients
with metastatic melanoma were accrued at each of the
three dose levels. Treatment was well tolerated. Serious
adverse events were rare and included hepatitis, hypo-
physitis, hypersensitivity reaction, elevated lipase and
colitis. Among 46 evaluable melanoma patients at the
time of analysis, 15 partial responses were observed, all
ongoing at a minimum follow up of 5+ months, con-
firming the safety and antitumor activity of MDX-1106.
Based on the promising clinical results and supporting
preclinical data, additional studies are under considera-
tion, including combinations of anti PD1 and anti
CTLA-4 mAb, or anti-PD1 with IL2 or IFN.
Evidence of clinical benefit of vaccination in patients
with melanoma was given in a presentation of a phase III
multi-institutional randomized study of immunization
with gp100:209-217(210 M) peptide followed by high
dose IL-2 vs. high dose IL-2 alone in patients with meta-
static melanoma. Previously a phase II study showed
objective responses in 42% of patients with metastatic
melanoma receiving high-dose (HD) IL-2 plus gp100
peptide. Other studies showed a lower response rate (RR)
but no randomized studies had been done. A prospective
randomized (1:1) phase III trial was conducted at 21 cen-
ters enrolling 185 patients with stage IV or locally
advanced stage III cutaneous melanoma, HLA A0201, no
brain metastases, eligible for HD IL-2, no previous HD
IL-2 or gp100 and ECOG 0 or 1. Arm 1 received HD IL-
2 alone (720,000 IU/kg/dose) and Arm 2 gp100:209-217
(210 M) peptide + Montanide ISA-51 each cycle followed
by HD IL-2. The primary objective was to compare clini-
cal response of HD IL-2 with and without gp100 vaccine.
Secondary objectives were to evaluate toxicity, progres-
sion free survival, immunologic response and quality of
life. Central HLA typing, pathology review, and blinded
response assessment were done at the NIH. From 2000
to 2007 185 patients were enrolled and 93 were treated
in Arm1 and 86 in Arm 2. Pretreatment patient charac-
teristics were well balanced except for a trend of younger
patients in the vaccine arm. Toxicities were consistent
with HD IL-2 ± vaccine, and manageable with medica-
tions. Investigator and central response assessment
showed significant improvement in overall RR and pro-
gression free survival for Arm 2. Patients with lung
metastases (M1b) accounted for the majority of the
response difference. A trend for increased overall survival
with gp100 vaccine was observed, with a median overall
survival in Arm 2 of 17.6 months versus 12.8 in Arm 1.
Median follow up for surviving patients was 41.5 months.
In a 12 day in-vitro sensitization assay of PBMC, the level
of vaccination was low (19%) and did not correlate with
clinical response, confirming previous studies. Increased
T regulatory cells (CD4+foxp3+) in responders after 4
cycles of treatment was seen in both treatment arms. In
conclusion gp100 enhanced the clinical activity of HD
IL-2 in patients with metastatic melanoma. Rational com-
binations of vaccines and immunomodulatory agents like
Table 2 Results from Phase II clinical study in Non-Small Cell Lung Cancer (NSCLC) with a median follow-up time of
44-months [16]
Phase II NSCLC (NCT 00290355) Results recMAGE-A3 + AS02B
Primary endpoint DFI HR: 0.75 (95% CI: 0.46-1.23)
recMAGE-A3 + AS02B vs. Placebo
p = 0.127 in favor of MAGE-A3 ASCI
Secondary endpoints Safety Well tolerated
Humoral immune response Response induced in > 98% patients
Cellular immune response Response induced in 41% patients
DFI: disease Free Interval.
HR: Hazard Ratio.
CI: Confidence Interval.
NSCLC: Non-Small Cell Lung Cancer.
Table 3 Gene signature associated to clinical benefit
of MAGE-A3 ASCI: Identification in Phase II study in
melanoma patients and confirmation in NSCLC
patients [17]
Phase II studies evaluating the MAGE-A3 ASCI
Phase II NSCLC
(NCT 00290355)
Phase II Melanoma
(NCT 00086866)
GS- 25% relative improvement (DFI) OS of 16.2 months
GS+ 53% relative improvement (DFI) OS of 28.0 months
GS-: Population in which the gene signature was not found.
GS+: Population for which a specific Gene Signature has been defined.
DFI: Disease Free Interval.
OS: Overall Survival.
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IL-2 need to be further studied in the treatment of
patients with metastatic melanoma [18].
Alterations in chromatin structure profoundly influ-
ence gene expression during normal cellular homeosta-
sis and malignant transformation. Methylation of
cytosines within CpG islands located in promoter and
proximal coding regions facilitates recruitment of
chromatin-remodeling proteins, which inhibit gene
expression. Post-translational modifications, such as
acetylation, methylation, and phosphorylation, of core
histone proteins ‘’mark’’ regions of chromatin for recog-
nition by multiprotein complexes, which either promote
chromatin relaxation and gene expression, or chromatin
compaction and repression of gene expression. Epige-
netic modification are reversible pharmacologically and
exploitable for the development of more efficacious
immunotherapeutic regimens. Along this line the poten-
tial of the DNA hypomethylating drug, 5-aza-2’-deoxy-
cytidine (5-AZA-CdR), to modulate the expression of
cancer testis antigens (CTA) and of HLA class I anti-
gens by melanoma xenografts, and the resulting modifi-
cations in immunogenicity of neoplastic cells was
investigated. Molecular analyses demonstrated a de
novo, long-lasting expression of the CTA MAGE-1, -2,
-3, -4, -10, GAGE 1-6, NY-ESO-1, and the upregulation
of the constitutive levels of MAGE-1, MAGE-3, and
NY-ESO-1 in melanoma xenografts from 5-AZA-CdR-
treated mice. Serological and biochemical analyses iden-
tified a de novo expression of NY-ESO-1 protein and a
concomitant and persistent upregulation of HLA class I
antigens. It was also observed that the generation of
anti-NY-ESO-1 antibodies in Balb/C mice immunized
with 5-AZA-CdR-treated human melanoma cells. In
addition, treatment with 5-AZA-CdR induced a persis-
tent expression of MAGE-1 in melanoma cells, and sig-
nificantly enhanced the constitutive expression of HLA
class I antigens and of the costimulatory molecules on a
panel of melanoma cells. Altogether, the data obtained
identify an immunomodulatory activity of 5-AZA-CdR
in vivo and strongly support the design of novel strate-
gies for clinical CTA-based chemo-immunotherapy for
melanoma patients.
New Molecules And New Strategies
After the failure of sorafenib, other more selective inhi-
bitors that target the mutated BRAF kinase have been
developed and are currently being evaluated in clinical
trials. At the moment, the two that appear to be the
best BRAF inhibitors have been tested in clinical studies:
PLX4032 and GSK2118436. The phase I trials of both
agents were described and their toxicities and efficacy
were compared. The most frequent adverse event have
been rash (68%), arthralgia (48%), photosensitivity (42%),
and fatigue (32%) for PLX4032 and pyrexia (43%), rush
(30%) and headache (26%) for GSK2118436. A charac-
teristic toxicity of these drugs is the onset of cutaneous
squamous cell carcinoma (23% for PLX4032 and 7% for
GSK2118436) which was suggested to be at least in part
due to inhibition of wild-type BRAF kinase and
enhanced signaling through RAF 1 signaling. At the
maximum tolerated dose of 960 mg twice daily of
PLX4032 tumor responses were rapid, with onset seen
as early as 2 weeks of treatment by positron emission
tomography scan, and an 81% best overall response rate
is reported. In the phase II study treatment with
PLX4032 resulted in a progression free survival of 6.2
months showing significant tumor shrinkage in the
majority of patients (objective response rate occurred in
52% of patients) and median overall survival has not
been reached. For GSK2118436 phase II expansion at
150 mg BID has shown overall response rate of 77% and
responses were seen in many sites including brain. The
rapid emergence of drug resistance in some patients
treated with one of the other BRAF inhibitor highlights
the need to establish mechanisms resistance in order to
develop therapeutic strategies for overcoming or pre-
venting resistance. Mechanisms of primary resistance
based on alteration in MAP kinase signaling can poten-
tially be overcame by combined BRAF and MEK inhibi-
tion based on preclinical evidence, and is being studied
in a dose-escalation, phase IB/II study to investigate the
safety, pharmacokinetics, pharmacodynamics and clinical
activity of the BRAF inhibitor GSK2118436 in combina-
tion with the MEK Inhibitor GSK1120212 in subjects
with BRAF mutant metastatic melanoma. Preliminary
investigations into mechanisms of secondary resistance
in patients treated with PLX4032 have suggested
PDGFRb or IGFR expression, emergence of NRAS
mutation, and upregulation of COT/TPL2 suggest that
targeting these molecules in combination with BRAF
may extend the benefit of this approach. Preliminary
evidence suggests that oncogenic BRAF contributes to
immune escape and that blocking its activity via MAPK
pathway inhibition leads to increased expression of mel-
anocyte differentiation antigens whose recognition of is
a critical component of the immunologic response to
melanoma. However, treatment with MEK inhibitors
impairs T lymphocyte function, whereas T-cell function
is preserved after treatment with a specific inhibitor of
BRAF. Thus, combinations of BRAF inhibitors with
immunotherapy may be another rational direction to
pursue.
These findings have important implications for com-
bined kinase-targeted therapy plus immunotherapy for
melanoma. In fact, various possible approaches for com-
bined therapy of advanced melanoma were described.
Recent data from trials testing targeted agents or
immune modulators, showed an improved survival with
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ipilimumab and efficacy in inhibition of mutated, acti-
vated BRAF that will lead to new strategies of treatment.
These includes target agents as BRAF-inhibitor with
greater selectivity, MEK inhibitors that show efficacy in
both BRAF mutated and NRAS mutated patient and
c-Kit inhibitors in patients with c-kit mutated mela-
noma. Although response rates with these molecules are
high, most are not durable due to the development of
resistance to treatment. For example PTEN loss and
cyclinD1 amplification are important regulators of
intrinsic resistance to BRAF inhibitors. Combined PI3K
and BRAF inhibitors therapy could help to overcome
resistance. For immune modulators, among those that
block immune checkpoint, in addition to anti-CTLA-4,
anti-PD-1 also showed responses in metastatic mela-
noma patients and, furthermore, the combination of
both in sub-efficacious doses demonstrated efficacy in a
mouse model. Positive results are also emerging from
studies of immune modulators that stimulate immune
system as anti-CD137, anti-OX40, anti-CD40, anti TGF
beta and anti 1-MT. Based on preclinical study findings,
new possible targets for melanoma therapy are Notch,
involved in embryonic pathways, NF-kB, given its domi-
nance in the regulation of growth signals and in the
immune and inflammatory response and PI3K inhibi-
tors, that, already used in phase I clinical trial, demon-
strated significant antitumor activities in breast cancer.
Other fields of cancer immunotherapy that are prov-
ing fruitful are oncolitic immunotherapy, which is an
example OncoVEXGM-CSFand new immune modulators
antibodies as Darleukine, a fusion protein, consisting of
the human vascular targeting antibody L19 and of
human interleukin-2. The next challenge for melanoma
therapy will be, from the gene signature, to optimize the
treatment of individual patient using these active agents
sequentially or in combination each other or with tradi-
tional anticancer modalities such as chemotherapy,
radiation or surgery [19].
The adaptive immune response influences the beha-
vior of human tumors. In fact, characterization of the
tumor-infiltrating immune cells in large cohorts of
human colorectal cancers by gene expression profiling
and in situ immunohistochemical staining to evaluate
the expression levels of genes related to inflammation,
TH1 adaptive immunity, and immunosuppression sug-
gested that TH1 adaptive immunity has a beneficial
effect on clinical outcome [20]. Tissue microarrays to
investigate the in situ adaptive immune response in the
center of the tumor (CT) and the invasive margin (IM)
of 415 CRCs showed that tumors from patients without
recurrence had higher immune cell densities (CD3,
CD8, GZMB, and CD45RO) within each tumor region
(CT and IM), than did those from patients whose
tumors had recurred. For all the markers of the
combined analysis of CT plus IM regions demonstrated
that coordinated adaptive immune reaction more than
tumor invasion predicts clinical outcome. Collectively,
the immunological data (the type, density, and location
of immune cells within the tumor samples) were found
to be a better predictor of patient survival than the his-
topathological methods currently used to stage colorec-
tal cancer [21,22]. Hence the concept of ‘’immune
contexture’’ as the combination of immune variables
associating the nature, density, functional orientation
and distribution of immune cells within the tumor of a
natural in situ immune reaction [23,24]. In order to
understand the mechanisms underlying immune
responses in colorectal cancer data integration and bio-
molecular network reconstruction are applied. The pre-
sence of specific chemokines (CX3CL1, CXCL10,
CXCL9) correlate with high densities of T-cell subpopu-
lations within specific tumor regions and their high
expression with prolonged disease-free survival [25].
According to an immune score based on the evaluation
of CD45RO-CT/IM and CD8-CT/IM the prognostic sig-
nificance of immune criteria was compared with that of
the tumor extension criteria using the American Joint
Committee on Cancer/International Union Against
Cancer-TNM (AJCC/UICC-TNM) staging system.
Assessment of CD8+ cytotoxic T lymphocytes in com-
bined tumor regions provides an indicator of tumor
recurrence beyond that predicted by AJCC/UICC-TNM
staging [21,22,26]. Similarly there is a correlation
between the extent of immune cell density, tumor stage
and relapse in melanoma [27]. In addiction for most of
the malignancies is demonstrated over the time a corre-
lation between lymphocytic infiltration and survival
benefit for patients with cancers [24,28]. These findings,
though a revision of the current indicators of clinical
outcome, may help to better identify the high-risk
patients who would benefit from adjuvant therapy.
Since T lymphocytes mediate durable tumor regres-
sions after immunotherapy, TCR engineering adoptive
cell transfer strategies is devised to take the TCR genes
from one subject who rejected melanoma and use them
to engineer a melanoma-fighting immune system in
other subjects. Adoptive cell transfer (ATC) of spleno-
cytes from fully immunocompetent HLA-A2.1/Kb mice
transduced with a chimeric murine/human TCR specific
for tyrosinase (MART-1), together with lymphodepletion
conditioning, dendritic cell-based vaccination, and high
dose interleukin-2, had profound antitumor activity
against large established MHC-and antigen-matched
tumors. Genetic labeling with bioluminescence imaging
and positron emitting tomography reporter genes
allowed visualization of the distribution and antigen-
specific tumor homing of TCR transgenic T cells,
with trafficking correlated with antitumor efficacy.
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This approach, directly translatable to humans, lead to
developed of a study of gene modified immune cells in
which adoptive transfer of MART-1 F5 TCR engineered
peripheral blood mononuclear cells (F5) after a nonmye-
loablative conditioning regimen, are administrated with
of MART-126·35-pulsed dendritic cells and interleukin-
2, in patients with advanced melanoma. Early results
showed that the treatment involves hematological toxi-
city (neutropenic fevers, marrow aplasia) and transient
responses followed by progression. One of the potential
mechanisms of relapse is the decrease in frequency of
TCR transgenic cells after ACT. In addition the applica-
tion of a nanotechnology-based diagnostics as NACS
(Nucleic Acid Cell Sorting) and SCBC (Single Cell Bar-
code Chip) allowed evaluating the functional heteroge-
neity of MART-1 cytotoxic T lymphocytes of the same
patient and its relation with temporal profile of disease.
Next clinical trials are planned of association of F5 with
tremelimumab, NY ESO TCR, or vorinostat.
Most human melanomas contain tumor-reactive
T-cells. Using IL-2 these can be activated and grown in
vitro and than can be transferred back to a suitably pre-
pared patient along with systemic IL-2 to circumvent
the limited ability of vaccines to generate CTL. Objec-
tive clinical responses have been observed in patients
who received non-myeloablative chemotherapy prior to
the adoptive transfer of autologous melanoma-reactive
tumor-infiltrating lymphocytes (TILs) and successes
have also been achieved in the treatment of small brain
metastases. Indeed ACT with a nonmyeloablative pre-
parative regimen using TILs and interleukin-2 has
demonstrated to mediate complete and durable regres-
sion of melanoma brain metastases. Disadvantages of
this approach are that, since the assay for tumor recog-
nition is not perfect, some active TILs are discarded
inappropriately and selecting tumor reactive cultures
complicates and prolongs TILs growth making labor-
intensive TILs production and limiting its widespread
applicability. Therefore short-term TILs cultures have
been developed for which demonstrating tumor recogni-
tion is not required. These ‘’young TILs’’ can mediate
tumor regression in metastatic melanoma with manage-
able toxicity constituting the next chapter of ACT ther-
apy. Returning to the concept of TCR gene therapy, it
was shown that retroviral insertion of genes encoding
tumor-reactive TCRs can impart tumor recognition,
providing the means for generating potent Ag complex-
specific TCR genes for T cell adoptive immunotherapy.
This approach has proven effective against NY-ESO1 in
melanoma and synovial sarcoma patients and in at least
one patient targeting CEA in colorectal adenocarcinoma.
Genetically retargeting T-cells by inserting antibody-
based chimeric antigen receptors (e.g. anti CD19 and
anti VEGF-R2) or introducing other immunological
functions (such as “single chain” IL-12 secretion) are
also promising. Still, one of the main future directions
of research will remain identifying highly specific new
tumor target antigens to attack with these new
technologies.
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